FDA adds bemotrizinol to approved sunscreen ingredients in the U.S.
The facts
- The FDA added bemotrizinol to the list of permitted sunscreen active ingredients in the United States.
- Bemotrizinol is the first new sunscreen active ingredient added under the U.S. over-the-counter sunscreen system in more than 20 years, with several reports describing it as the first since the late 1990s or in more than 25 years.
- The ingredient has already been used for years in Europe and other markets outside the United States, including parts of Asia and Australia.
- According to the FDA, bemotrizinol protects against both UVA and UVB radiation and showed little irritation or absorption into the skin.
- Reports say the FDA cleared bemotrizinol for adults and for children 6 months and older.
- The decision is expected to expand sunscreen options for U.S. consumers, and some dermatologists say bemotrizinol offers broader or more stable UV protection than many ingredients currently available in the U.S.
- DSM Nutritional Products is expected to launch the ingredient in the U.S. later this year under the brand name Parsol Shield, and other manufacturers are expected to gain access after an 18-month exclusivity period.
Context
What is bemotrizinol?
Bemotrizinol is a chemical sunscreen filter that absorbs or blocks ultraviolet radiation, including both UVA and UVB rays NYT,Washington Post,NBC News.
Why is this FDA action getting attention?
It is the first time in more than two decades that the FDA has added a new active sunscreen ingredient for over-the-counter use in the U.S., ending a long stretch in which American sunscreen filters had not been updated USA Today,Washington Post,NBC News.
When will U.S. shoppers likely see products with it?
Multiple reports say DSM Nutritional Products plans to launch bemotrizinol in the U.S. later this year under the name Parsol Shield, with other manufacturers able to use it after an 18-month exclusivity period Yahoo! Finance,CBS News.
Common ground, and where they split
- Common ground
- A sunscreen ingredient long used abroad has finally cleared the U.S. over-the-counter system after more than two decades, adding an option the FDA says protects against UVA and UVB with little irritation or absorption for adults and young children.
- Where Left and Right split
- Less a disagreement than a question of emphasis: the approval as a public-health correction to a long U.S. lag in access to stronger protection, versus the approval as a market opening that gives consumers more sunscreen choices.
How left and right read it
What stands out is the long gap in the U.S. system before adding a new sunscreen ingredient, even though bemotrizinol had already been used for years in Europe and other markets outside the United States. Because the FDA says it protects against both UVA and UVB radiation, showed little irritation or skin absorption, and is cleared for adults and children 6 months and older, this expands protection options in a way that matters for families and public health.
What matters most is that the FDA has now permitted another active ingredient in a category that had gone more than 20 years without a new addition under the over-the-counter system. Reports say this should expand consumer choice, and the expected launch followed by later access for other manufacturers points to a market opening in which people can decide among more sunscreen options.
The receipts — 92 sources
Wire services (14)
Other coverage (78)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.